Antares Pharma, Inc. (ATRS)

[H2R]

Hi CYRXorbust, should be another fun ride, starting hopefully with a nice jump tomorrow, and then in the medium term :)

From an SoS article from May 9th (a fairly comprehensive view of the Company and projections),

I am assuming that the AB rated generic to EpiPen will be launched in 2018 as per guidance of Teva, but I am not sure if it will be sooner or later.
[...]
I estimate that Antares will realize pretax profits that amount to 10% of Teva’s peak sales. These peak sales are likely to be reached quickly, probably within three or four quarters of launch. On peak sales of $156 million, Antares would realize pretax profits of $15.6 million. Assuming a 21% tax rate and 156 million outstanding shares the contribution to EPS would be $0.08 per share.

https://smithonstocks.com/antares-recent-launch-of-makena-subcu-auto-injector-and-probable-launches-of-xyosted-and-ab-rated-generic-to-epipen-could-make-for-an-outstanding-price-performance-in-2018-atrs-buy-2-36/

Best of luck with your investments!